Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial of SHR-1139 in Healthy Volunteers
Sponsor: Atridia Pty Ltd.
Summary
The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose of SHR-1139 in healthy volunteers
Official title: A Phase 1, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Subcutaneous/Intravenous Administered SHR-1139 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-08-19
Completion Date
2026-09-30
Last Updated
2026-03-19
Healthy Volunteers
Yes
Conditions
Interventions
SHR-1139 Injection
Single dose of SHR-1139 given subcutaneously (dose level 1 )
SHR-1139 Injection
Single dose of SHR-1139 given subcutaneously (dose level 2 )
SHR-1139 Injection
Single dose of SHR-1139 given intravenously (dose level 3)
Locations (1)
Linear
Perth, Western Australia, Australia